GLPwatch
Papers (9189)
Page 144 of 154, ranked by citation count.
- [Effects of semaglutide on mental health].
- Severe euglycemic ketoacidosis following combined therapy with GLP-1 receptor agonist and SGLT-2 inhibitor, refractory to standard treatment: a case report.
- Effect of Adherence to Oral Semaglutide on Glycemic Control in People With Type 2 Diabetes Treated With Metformin: Protocol for an Open-Label Clinical Trial.
- Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.
- Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk.
- [GLP-1 receptor activation effects the p38MAPK signal pathway in hepatic stellate cells].
- [Liraglutide in polycystic ovary syndrome].
- [Changes in weight and diabetes compensation (HbA1c) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBYII study (observations lasting 24 months)].
- New drugs: Liraglutide, dalfampridine, and abobotulinumtoxinA.
- From In Vitro Efficacy to Long-Term HbA1c Response for GLP-1R/GlucagonR Agonism Using the 4GI-HbA1c Systems Model.
- Chemogenetic inhibition of the lateral hypothalamus effectively reduces food intake in rats in a translational proof-of-concept study.
- Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg.
- Comparative Gynecological Safety of the Dual GIP/GLP-1 Receptor Agonist Tirzepatide vs. the GLP-1 Receptor Agonist Semaglutide: A Real-World Pharmacovigilance Analysis (2022-2025).
- Semaglutid bessert HFpEF-Herzinsuffizienz.
- More on Semaglutide in Early Type 1 Diabetes. Reply.
- Semaglutide and Cardiovascular Outcomes.
- Could semaglutide be related to increasing the risk of developing a disordered eating?
- [GLP-1 agonists: an overview].
- Semaglutide's CVD indication could cost US Medicare $145bn extra a year.
- Childhood Obesity, Medications, and Surgeries.
- Exendin-4 alleviates Aβ1-40-induced apoptosis and calcium dysregulation in RPE cells through the CHP1/NHE1 complex.
- GLP-1 receptor agonists, SGLT-2 inhibitors, and their combination: effects on carotid atherosclerosis regression, oxidative stress, and amyloid-β1-40 in diabetes.
- Exendin-4 improves mitochondrial integrity against cisplatin-induced cardiac damage: Targeting p53 and NF-κB pathways.
- Insulin Autoimmune Syndrome: Imaging Findings and Uptake Pattern With 68 Ga-Exendin-4 and 68 Ga-DOTATATE PET-CT.
- Liraglutide Attenuates Endothelial Dysfunction by Inhibiting Hyperglycemia-Induced Endothelial Cell Senescence Through the LARP7/SIRT1 Pathway.
- New combination therapy shows promise for recent-onset type 1 diabetes mellitus.
- Beyond Diabetes: The Vasculoprotective Effects and Anti-Atherosclerotic Potential of Tirzepatide.
- Can early use of insulin, GLP-1 halt diabetes progression?
- Preventive effect of liraglutide on postoperative delirium in elderly patients undergoing cardiac surgery: protocol for a single-centre, randomised, double-blind, placebo-controlled trial.
- Exenatide, a glucagon-like peptide-1 receptor agonist, may negatively impact bone healing in rats: histopathological, biochemical, and in silico findings.
- Atypical Antipsychotics-Induced Glucose and Lipid Metabolism Disorders and Therapeutic Intervention.
- Weight Loss Medications for Adult Patients With Obesity and Binge Eating-A Systematic Review and Meta-analysis.
- Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesity-Reply.
- Response to: Letter to the Editor Regarding Efficacy of IDegLira Versus IDegAsp Therapy in Patients with Type 2 Diabetes: A Randomized Crossover Study by isCGM.
- [In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve and maintain good glycemic control?]
- New Indication for Weight Loss Drug Semaglutide.
- [Optimizing treatment of type 2 diabetic patients].
- Semaglutide: new dawn for diabetics.
- [Case report: successful treatment with liraglutide in an insulin allergic patient with liver cirrhosis, hepatocellular carcinoma and poor glycemic control using high dose of insulin].
- [Changes in weight and diabetes compensation (HbA(1c)) in patients with diabetes mellitus type 2 after adding exenatide (Byetta) to the current treatment in 28 diabetology departments in the Czech Republic - BIBY-I study (observations lasting 3 to 12 months)].
- Semaglutide Linked With Lower Risk of Suicidal Thoughts.
- An Open-Label, Single-Center Proof of Concept Study Evaluating the Efficacy and Safety of Tirzepatide for Moderate to Severe Hidradenitis Suppurativa.
- Efficacy and safety of Tirzepatide in patients with heart failure with preserved ejection fraction: A systematic review and meta-analysis.
- An analysis of dosage volume for halfway doses in the Victoza Pen.
- Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population.
- The role of combination therapy in type 2 diabetes in the post-ACCORD era.
- Evaluating the effects of liraglutide, empagliflozin and linagliptin on mild cognitive impairment remission in patients with type 2 diabetes (LIGHT-MCI): study protocol for a multicentre, randomised controlled trial with an extension phase.
- Newer classes of antidiabetes drugs: ophthalmological considerations for GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
- Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes.
- [Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].
- Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study.
- Blockbuster obesity drug leads to better health in people with HIV.
- Semaglutide in Patients Undergoing Anesthesia for Otolaryngologic Procedures.
- Reply.
- La metformine comme stabilisateur de poids après l’arrêt du sémaglutide ?
- The real-world observational prospective study of health outcomes with dulaglutide and liraglutide in type 2 diabetes patients (TROPHIES): resource use and costs of treatment in clinical practice in France, Germany, and Italy.
- Real world study of GLP-1 receptor agonists in overweight or obese type 2 diabetes by using repeated measurement analysis of variance.
- Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.
- Drug Combo Adds No Benefit in Patients with Type 2 Diabetes.
- Survodutide: A Dual GLP-1/Glucagon Agonist Reshaping Cardiometabolic Care.